Compare ETS & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETS | GTBP |
|---|---|---|
| Founded | 2020 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 8.5M |
| IPO Year | 2025 | N/A |
| Metric | ETS | GTBP |
|---|---|---|
| Price | $0.53 | $0.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 83.3K | ★ 1.8M |
| Earning Date | 04-14-2026 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,585,885.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.59 | N/A |
| 52 Week Low | $0.49 | $0.54 |
| 52 Week High | $4.23 | $3.85 |
| Indicator | ETS | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 48.32 |
| Support Level | $0.52 | $0.69 |
| Resistance Level | $0.58 | $0.73 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 38.07 | 54.42 |
Elite Express Holding Inc is a holding company that operates through its wholly owned subsidiary and specializes in last-mile delivery services within California. Its core business focuses on retrieving packages from distribution hubs and ensuring their prompt and secure delivery to recipients' doorsteps. Committed to innovation and efficiency, its mission is to optimize last-mile logistics by providing efficient, reliable, and innovative delivery solutions. The company mainly competes in the route delivery industry, which has several material barriers of entry, including: Substantial time and capital investment, Technological proficiency, Regulatory barriers, Balancing service quality and cost efficiency, and Effective Management.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.